WN 1316

Drug Profile

WN 1316

Alternative Names: WN1316

Latest Information Update: 18 Mar 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Neugen Pharma; Wakunaga Pharmaceutical
  • Developer Neugen Pharma
  • Class Acetamides; Cytoprotectives; Imidazoles; Neuroprotectants; Pyridines; Small molecules
  • Mechanism of Action Antioxidants; Astrocyte inhibitors; Glial cell inhibitors; Neuronal apoptosis-inhibitory protein stimulants; NF E2 related factor 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis

Most Recent Events

  • 05 Mar 2015 Neugen Pharma completes an investigator-sponsored phase I trial in Amyotrophic lateral sclerosis (In volunteers) in Japan (PO) (UMIN000015054)
  • 10 Sep 2014 Phase-I clinical trials in Amyotrophic lateral sclerosis (In volunteers) in Japan (PO) (UMIN000015054)
  • 01 Sep 2013 Preclinical trials in Amyotrophic lateral sclerosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top